Draxxin (tulathromycin) Injectable Solution: Efficacy in the treatment of experimentally- induced Mycoplasma hyopneumoniae pneumonia in pigs

  • Shelley L. Stanford
  • Published 2008

Abstract

ycoplasma hyopneumoniae causes mycoplasmal pneumonia of swine (MPS), one of the most prevalent and costly of swine diseases. A USDA National Animal Health and Monitoring Survey (NAHMS) undertaken in 2001 found that producers in the U.S. thought M. hyopneumoniae was a concern in approximately 20% of nursery pigs on 29% of the farms surveyed. Moreover, in operations with more than 10,000 pigs, mycoplasma-associated disease was considered important in 53% of the sites with nursery pigs and 68% of the sites with finisher pigs. Diagnostically, M. hyopneumoniae was identified in more than 50% of the sites. Pigs of all ages are susceptible to MPS; however, disease occurs most often in growing and finishing pigs. Once established, MPS persists in infected herds, varying in severity with season, ventilation, and concentration of swine. Clinical signs include a chronic, nonproductive cough continuing for weeks or months, depressed appetite, listlessness, labored breathing, reduced feed efficiency, nasal discharge, unthrifty appearance, and retarded growth. Stunting may be evident, resulting in considerable variation in size among affected pigs. Even at low levels of infection, MPS causes significant economic losses due to reduced feed efficiency, lower daily M

Cite this paper

@inproceedings{Stanford2008DraxxinI, title={Draxxin (tulathromycin) Injectable Solution: Efficacy in the treatment of experimentally- induced Mycoplasma hyopneumoniae pneumonia in pigs}, author={Shelley L. Stanford}, year={2008} }